skip to content


Obesity and COVID-19: when two pandemics collide

24 September 2022

Elderberries, flaxseeds, manuka honey, garlic and the juice of an orange. A recipe for a vampire-repelling poultice, perhaps? No, but these ingredients have all made their way from ancient folklore into current public consciousness as “immune-boosting superfoods”. The midst of a global infectious disease pandemic is a...

Read more

Nature Communications featured article: Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report

1 March 2021

A recently publised article from Dr. James Thaventhiran's group about the potential treatment effect of remedesvir in COVID-19 patients was chosen as a featured paper by Nature Communiactions. The scientific achivement is highlighted under the topic of "Microbiology and Infectious diseases" in the journal's January issue .

Read more

Remdesivir likely to be highly effective antiviral against SARS-CoV-2

14 December 2020

The drug remdesivir is likely to be a highly effective antiviral against SARS-CoV-2, according to a new study by a team of UK scientists. Writing in Nature Communications, the researchers describe giving the drug to a patient with COVID-19 and a rare immune disorder, and observing a dramatic improvement in his symptoms and...

Read more

Researchers test a drug that may allow more cancer patients to benefit from immunotherapy in the future

3 November 2020

Immunotherapy can be a lifesaver for cancer patients, but some patients' tumours don't respond well to this treatment. However, researchers are encouraged by a recent clinical trial that suggests that it may be possible to expand immunotherapy to help more people in the future. Immunotherapy works by marshalling the body's...

Read more

Dr James Thaventhiran joins Dr Nicholas Matheson for the CITIID's weekly COVID-19 update

21 April 2020

On the 16th April, Dr James Thaventhiran joined Dr Nicholas Matheson for the Cambridge Institute of Therapeutic Immunology and Infectious Disease's (CITIID) weekly COVID-19 update. This talk, along with all other previous updates from the CITIID, can be found here. Details of the weekly webinar can be found here . Each...

Read more

Thaventhiran lab's publication selected as one of the top ten papers of 2019 by the Journal of Experimental Medicine

19 March 2020

The Thaventhiran lab's paper 'Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses' has been selected as one of the Top Ten Papers of 2019 by the Journal of Experimental Medicine (JEM). Brief Definitive Report Interleukin-6 receptor deficiency Sarah Spencer; Sevgi Köstel...

Read more